• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.

作者信息

Andreasen F, Mikkelsen E

出版信息

Eur J Clin Pharmacol. 1977 Aug 17;12(1):15-22. doi: 10.1007/BF00561400.

DOI:10.1007/BF00561400
PMID:902673
Abstract

After furosemide 40 mg i. v. its plasma concentration was significantly higher during an 8-hour period in 6 patients with left sided heart failure than in 8 normal subjects. The plasma clearance was significantly lower in the patients than in the normal subjects--1.23 and 2.34 ml/kg/min, respectively. The apparently smaller volume of distribution in the cardiac patients (0.140 1/kg and 0.181 1/kg, respectively) was not significantly different. In the group of normal subjects, whose ages ranged from 27 to 74 years, no correlation was found between age and either plasma clearance or volume of distribution. In all the patients, the renal clearance of furosemide rose from the first to the second hour after the injection (average +/- SD)--39 +/- 17 and 77 +/- 51 ml/min. In normal subjects, the average values did not change--116 +/- 79 and 117 +/- 54 ml/min. The urinary excretion of furosemide and a metabolite (probably a glucuronide) was measured in 16 individuals. 24-hour urines from all the subjects investigated contained between 20 and 30 mg unchanged furosemide (average 25.2 mg). In addition, between 2.7 and 11.2 mg (average 6.7 mg) furosemide was excreted as the metabolite in five patients who had been treated with furosemide for at least the preceding 6 months. An average of 0.8 +/- 0.8 mg of the metabolite was found in 11 subjects who had not previously been treated with furosemide.

摘要

相似文献

1
Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.
Eur J Clin Pharmacol. 1977 Aug 17;12(1):15-22. doi: 10.1007/BF00561400.
2
Effect of furosemide in congestive heart failure.
Clin Pharmacol Ther. 1981 Aug;30(2):177-82. doi: 10.1038/clpt.1981.145.
3
Hydralazine and furosemide kinetics.
Clin Pharmacol Ther. 1982 Sep;32(3):303-6. doi: 10.1038/clpt.1982.164.
4
The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.使用高效液相色谱法来阐明速尿及其代谢产物的代谢和尿排泄情况。
Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):223-9. doi: 10.1111/j.1600-0773.1981.tb00897.x.
5
Pharmacokinetics of furosemide in patients with congestive heart failure.
Pharmacology. 1979;19(3):121-31. doi: 10.1159/000137299.
6
Biotransformation of furosemide in kidney transplant patients.呋塞米在肾移植患者中的生物转化。
Eur J Clin Pharmacol. 1983;24(6):787-90. doi: 10.1007/BF00607088.
7
Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.速尿在充血性心力衰竭中的稳态吸收动力学和药效学
Int J Clin Pharmacol Ther Toxicol. 1987 Mar;25(3):123-8.
8
Furosemide disposition in cirrhosis.
Clin Pharmacol Ther. 1982 Jun;31(6):719-25. doi: 10.1038/clpt.1982.101.
9
Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
Eur J Clin Pharmacol. 1985;28(1):53-9. doi: 10.1007/BF00635708.
10
Biotransformation of furosemide in patients with acute pulmonary edema.速尿在急性肺水肿患者中的生物转化
Drug Metab Dispos. 1979 Nov-Dec;7(6):383-7.

引用本文的文献

1
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload.一个用于模拟在患有心力衰竭和容量超负荷的青少年中皮下注射固定剂量呋塞米的成人群体药代动力学模型。
Clin Pharmacokinet. 2025 May 13. doi: 10.1007/s40262-025-01515-2.
2
Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: Discovery of putative organic anion transporter biomarkers.丙磺舒对大鼠呋塞米血药浓度和内源性化合物的肾排泄及潜在有机阴离子转运体生物标志物的影响。
Biochem Pharmacol. 2023 Dec;218:115867. doi: 10.1016/j.bcp.2023.115867. Epub 2023 Oct 20.
3

本文引用的文献

1
FUROSEMIDE (LASIX) AS A DIURETIC.
Acta Med Scand. 1965 Jun;177:777-82.
2
Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure.胃肠外给药后血液中的奎尼丁浓度及尿液排泄与充血性心力衰竭的关系。
Acta Med Scand. 1957 Nov 15;159(2):105-9. doi: 10.1111/j.0954-6820.1957.tb00111.x.
3
Intravenous administration of furosemide in heart failure.心力衰竭时静脉注射呋塞米。
JAMA. 1967 Jun 5;200(10):824-9.
From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion.
从口服速尿到皮下注射速尿:通往治疗充血新机遇之路
Struct Heart. 2022 Aug 7;6(4):100076. doi: 10.1016/j.shj.2022.100076. eCollection 2022 Aug.
4
Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.摄取和外排转运体对呋塞米口服药代动力学的贡献。
ACS Omega. 2020 Dec 15;5(51):32939-32950. doi: 10.1021/acsomega.0c03930. eCollection 2020 Dec 29.
5
The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.心力衰竭对心血管和非心血管药物药代动力学的影响:对证据的批判性评估。
Br J Clin Pharmacol. 2019 Jan;85(1):20-36. doi: 10.1111/bcp.13760. Epub 2018 Oct 14.
6
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).心力衰竭患者药物的临床药代动力学:更新(第 1 部分,静脉内给药的药物)。
Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2.
7
Extrahepatic metabolism of frusemide in anaesthetized rabbits.速尿在麻醉兔体内的肝外代谢
Br J Pharmacol. 1995 Nov;116(5):2407-12. doi: 10.1111/j.1476-5381.1995.tb15087.x.
8
Pharmacokinetics of loop diuretics in congestive heart failure.袢利尿剂在充血性心力衰竭中的药代动力学
Br Heart J. 1994 Aug;72(2 Suppl):S40-3. doi: 10.1136/hrt.72.2_suppl.s40.
9
Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.丙磺舒抑制速尿及其酰基葡萄糖醛酸苷的肾脏清除率。
Br J Clin Pharmacol. 1995 Jun;39(6):692-5.
10
Pharmacokinetic changes in patients with oedema.水肿患者的药代动力学变化。
Clin Pharmacokinet. 1995 May;28(5):405-18. doi: 10.2165/00003088-199528050-00005.
4
Absorption and excretion of furosemide-S35 in human subjects.人体受试者中速尿-S35的吸收与排泄
Proc Soc Exp Biol Med. 1966 Oct;123(1):17-22. doi: 10.3181/00379727-123-31391.
5
Potential effect of the plasma on drug distribution.血浆对药物分布的潜在影响。
Nature. 1965 Jul 17;207(994):274-6. doi: 10.1038/207274a0.
6
Concept of a volume of distribution and possible errors in evaluation of this parameter.分布容积的概念以及该参数评估中可能存在的误差。
J Pharm Sci. 1968 Jan;57(1):128-33. doi: 10.1002/jps.2600570125.
7
Problems associated with analysis of pharmacokinetic models.与药代动力学模型分析相关的问题。
J Pharm Sci. 1971 Jun;60(6):882-5. doi: 10.1002/jps.2600600616.
8
Procainamide dosage schedules, plasma concentrations, and clinical effects.普鲁卡因胺的给药方案、血浆浓度及临床效果。
JAMA. 1971 Mar 1;215(9):1454-60.
9
Drug elimination and apparent volume of distribution in multicompartment systems.多室系统中的药物消除与表观分布容积
J Pharm Sci. 1972 Jun;61(6):952-4. doi: 10.1002/jps.2600610630.
10
Furosemide concentrations in serum and urine, and its binding by serum proteins as measured fluorometrically.通过荧光法测定的血清和尿液中呋塞米的浓度及其与血清蛋白的结合情况。
Clin Chem. 1974 Feb;20(2):152-8.